The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter phase II trial of ramucirumab plus irinotecan in patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S-1 therapy: RAMIEL trial (OGSG1901).
 
Atsushi Takeno
No Relationships to Disclose
 
Toshifumi Yamaguchi
Honoraria - MSD Oncology; Ono pharmaceutical., Co LTD
Consulting or Advisory Role - Daiichi Sankyo Company, Limited
 
Yusuke Akamaru
No Relationships to Disclose
 
Hidekazu Hirano
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Fujifilm; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Amgen (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Taiho Pharmaceutical (Inst)
 
Masaaki Motoori
No Relationships to Disclose
 
Yoshihiro Kakeji
Honoraria - Bristol Myers Squibb; Chugai Pharma; Covidien; DAIICHI SANKYO COMPANY, LIMITED; Johnson & Johnson; Lilly; Merck; Merck Sharp and Dohme; Miyarisan pharmaceutical; Nippon Kayaku; Olympus Marketing, Inc.; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Tsumura & Co.; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Yosuke Kito
Honoraria - Chugai Pharma; Daiichi Sakyo; Ono Pharmaceutical; Takeda
 
Takashi Nomura
No Relationships to Disclose
 
Takeshi Kawakami
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly; Micin; MSD; Ono Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo
 
Masahiro Tanemura
No Relationships to Disclose
 
Hiroyuki Okuda
No Relationships to Disclose
 
Tomohiro Matsushima
No Relationships to Disclose
 
Toshio Shimokawa
No Relationships to Disclose
 
Yukinori Kurokawa
Honoraria - Astellas Pharma; Daiichi Sankyo; Johnson & Johnson; Lilly; MC Medical; Medtronic; MSD; Nippon Kayaku; Ono Pharmaceutical; Stryker; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Shunji Endo
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD K.K; Ono Pharmaceutical; Takata Phamaceutical
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Daiichi-Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiihi-Sankyo; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); SHIONOGI (Inst); Yakult Honsha (Inst)